78 Discovery of a novel anti-TACI antibody with SLE treatment effect and limited side-effect. (April 2019)

• Record Type: Journal Article
• Authors: Feng, Xiao; Sun, Dawei; Qin, Suofu; Wang, Tao; Yan, Hongbao; Teng, Guosheng; Che, Chong
• Is Part Of: Lupus science & medicine. Volume 6(2019)supplement 1
• Page Start: A56
• Page End: A56
• Publication Date: 2019-04
• Subjects: Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1136/lupus-2019-lsm.78
• Languages: English
• ISSNs: 2398-8851

Abstract

Abstract : Background: All clinical trials involving the BAFF axis to date have targeted the ligand, BAFF. Remarkably, there have been no reports of targeting any of the BAFF receptors, BCMA, TACI, or BR3. TACI is critical for T cell-independent type antibody production and memory B cell survival. Also IgG autoantibody production in SLE patient is mainly a T cell-independent. Thus, TACI is a promising target for SLE treatment. Methods: In this study, we discovered a novel anti-TACI antibody, GenSci-X002, by hybridoma and humanization approach to investigate its funtion on SLE treatment. Results: GenSci-X002 specifically binds to TACI receptor with sub-nanomolar affinity and blocks the binding of TACI and BAFF ligand. Also, GenSci-X002 neutralized BAFF-TACI downstream signal in a luciferase reporter assay. In SLE mouse model, GenSci-X002 exhibited equivalent SLE treatment effects with Belimumab, evidenced by the significant decrease of pathogenic autoantibody production, kidney Ig deposition and the development of nephritis. Remarkably, GenSci-X002 didnt alter normal B cell subsets and B cell numbers with minimal side effect. Conclusions: Here, we show that anti-TACI antibody protected against BAFF-mediated autoimmune manifestations while preserving B cells, suggesting that loss of BAFF signaling through TACI rather than loss of B cells may underpin the effect of Belimumab in the clinic. Therefore, B cell blockade of TACI by GenSciX002 may offer a more specific and safer therapeutic alternative to broad B cell depletion in SLE. The candidate therapeutics, GenSci-X002, will be further studied in preclinical evaluation to enter early-stage clinical trials of SLE in future. Funding Source(s): None